期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 96, 期 6, 页码 672-683出版社
WILEY
DOI: 10.1038/clpt.2014.174
关键词
-
资金
- National Institutes of Health [DA-08924, NS-048295, AG-35844, HL-101186, AG-0001751, AG-042637]
- Research Program in Mitochondrial Therapeutics at the Weill Cornell Medical College
The mitochondrial electron transport chain (ETC) plays a central role in energy generation in the cell. Mitochondrial dysfunctions diminish adenosine triphosphate (ATP) production and result in insufficient energy to maintain cell function. As energy output declines, the most energetic tissues are preferentially affected. To satisfy cellular energy demands, the mitochondrial ETC needs to be able to elevate its capacity to produce ATP at times of increased metabolic demand or decreased fuel supply. This mitochondrial plasticity is reduced in many age-associated diseases. In this review, we describe the serendipitous discovery of a novel class of compounds that selectively target cardiolipin on the inner mitochondrial membrane to optimize efficiency of the ETC and thereby restore cellular bioenergetics in aging and diverse disease models, without any effect on the normal healthy organism. The first of these compounds, SS-31, is currently in multiple clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据